甘露寡糖对断奶仔猪肠道菌群的影响

选取28日龄断奶的三元[杜×(大×长)]杂交仔猪96头,平均体重为(7.46±0.38)kg,按体重和性别随机分为4个处理组,每个处理组3个重复,每个重复8头仔猪,公母各半。第一个处理组为空白组,第二、三、四个处理组在相同的基础日粮中分别添加0.1%、0.2%和0.4%的甘露寡糖,研究甘露寡糖对断奶仔猪肠道菌群的影响。结果表明:(1)各实验组肠道大肠杆菌的浓度极显著低于对照组;(2)第三组和第四组其结肠、盲肠和直肠中双歧杆菌增殖显著。第二组中只有结肠中双歧杆菌显著高于对照组,但盲肠和直肠中双歧杆菌增殖不明显;(3)各个处理组肠道中乳酸杆菌的浓度与对照组相比差异不显著。     

Syncope associated with swallowing in two British Bulldogs with unilateral carotid body tumours

Carotid body tumours were diagnosed in two British Bulldogs that each had a history of syncopal episodes induced by eating, drinking or pulling on the leash. In both dogs, a cervical mass was identified using computed tomography (CT) or magnetic resonance imaging, with carotid body tumour (CBT) being the histopathological diagnosis. A heart base mass was also identified in one dog by both CT and echocardiography. Swallowing syncope has been reported in the human literature in association with cervical mass lesions, but this is the first report in dogs. The present cases emphasise the value of advanced imaging of the head and neck in dogs presenting with clinical signs of syncope associated with swallowing and the importance of careful manipulation of the neck in patients with CBTs.     

Cardiovascular effects of butorphanol in isoflurane-anesthetized alpacas

Butorphanol has been used clinically to provide analgesia in alpacas, but cardiovascular effects have not been reported. Using a randomized cross‐over design, eight healthy, young adult female alpacas (3 ± 1 SD years) weighing 64 ± 9 SD kg were anesthetized with isoflurane by mask followed by tracheal intubation and maintenance of anesthesia with 1.75% et (isoflurane) in oxygen. Two treatments, butorphanol (0.1 mg kg^–1 IV) and control (saline, IV) were assigned to the animals in a randomized manner allowing a minimum of two weeks between treatments. While anesthetized, animals were instrumented for measurement of cardiovascular variables including systolic, diastolic, and mean arterial blood pressure, pulmonary arterial pressure, pulmonary capillary wedge pressure, central venous pressure, cardiac output (CO) and pulmonary temperature (TEMP). CO was measured via thermodilution using 5 mL of iced 5% dextrose and recording the average of three replicate measurements. Cardiac index, systemic vascular resistance (SVR) and pulmonary vascular resistance were also calculated. Arterial and mixed venous blood samples were collected for blood gas analysis [pH, pO₂, pCO₂, (HCO₃^?), BE, Hb_sat]. Variables were collected at baseline (time 0) and at 5, 10, 15, 30, 45, and 60 minutes following injection. Variables were analyzed by anova for repeated measures with post‐hoc differences between means identified using the Bonferroni comparison (p < 0.05). SVR decreased five minutes after administration of butorphanol (Huynh Feldt corrected p = 0.045) and remained decreased for 60 minutes. TEMP decreased with time in both groups (Huynh Feldt corrected p = 0.000027), but groups were not different between each other. Other cardiovascular and blood gas variables were not different between groups. We conclude that butorphanol (0.1 mg kg^–1 IV) had minimal effects on the cardiovascular system of these alpacas, causing a mild decrease in SVR.     

Effects of 2.0% end-tidal isoflurane with and without atropine prior to dexmedetomidine administration on cardiovascular variables in dogs

The purpose of this study was to determine the cardiovascular effects of 2.0% end‐tidal isoflurane in dogs administered dexmedetomidine (DEX). Using a randomized crossover design and allowing at least 2 weeks between treatments 12 adult hound dogs of either sex weighing 22 ± 1.7 SD kg were anesthetized by face mask administration of either sevoflurane or isoflurane to facilitate instrumentation prior to administration of treatment drugs. Dogs were intubated and instrumented to enable measurement of heart rate (HR), systolic (SAP), mean (MAP) and diastolic (DAP) arterial pressures, mean pulmonary arterial pressure (PAP), pulmonary capillary wedge pressure (PCWP), central venous pressure (CVP), pulmonary arterial temperature (TEMP), and cardiac output (CO) via thermodilution using 5 mL of 5% dextrose, and recording the average of three replicate measurements. Cardiac index (CI) and systemic (SVR) and pulmonary vascular resistances were calculated. Following completion of instrumentation, dogs were allowed to recover for 40 minutes. After collection of baseline data, dogs were administered one of four treatments at T‐10 minutes prior to injection of DEX (500? g M^–2 IM): 1) saline (SAL); 2) atropine [ATR, 0.02 (n = 6) or 0.04 (n = 6) mg kg^–1 IM]; 3) ISO (2.0% end tidal concentration); or 4) ISO + ATR. Cardiovascular data were collected at T‐20 and T‐5 minutes prior to administration of DEX, and at 5, 10 , 20, 30, 40, and 60 min following DEX. Data were analyzed using anova for repeated measures with post‐hoc differences between means identified using Bonferroni's method (p < 0.05). Differences in ATR dose were not found to be significant and thus results for ATR dose groups were pooled. Administration of SAL (dexmedetomidine alone) was associated with decreases in HR and CO and increases in SAP, MAP, DAP, CVP, and SVR. Administration of ATR was associated with an increase in HR and CO compared with SAL. Administration of ISO was associated with an increase in HR and a decrease in SVR, MAP and CVP compared with SAL. Administration of ISO + ATR was associated with effects similar to that of ISO or ATR alone. We conclude that administration of ISO reduces the increase in SVR associated with administration of DEX and does not adversely affect CO.     

Immunization of proteins from Toxascaris leonina adult worm inhibits allergic specific Th2 response

Recently, the influence of parasitic infections on the incidence of allergic diseases has become the focus of increased attention. In order to ascertain whether parasite-derived proteins could inhibit the allergic specific Th2 response, we applied excretory-secretory protein (Tl-ES) or total protein (Tl-TP) of the adult worm Toxascaris leonina to asthma model mice prior to or simultaneously with OVA challenge, after which we assessed the OVA-specific Th2 responses. The group subjected to immunization with Tl-ES and Tl-TP (immunized group) evidenced a thinning of the bronchial epithelial and muscle layer, a disruption and shedding of epithelial cells, a reduction in the number of goblet cells, and a reduction in mucus production as compared to the group treated with Tl-ES coupled with OVA challenge (challenge with OVA groups) and the OVA-induced asthma group. The administration of Tl-ES and Tl-TP, regardless of injection time, was shown to inhibit the recruitment of inflammatory cells into the airway, and in particular, macrophages, neutrophils, and lymphocytes were significantly reduced as the result of the parasite proteins. However, the total number of eosinophils was slightly reduced as the result of the administration of parasite proteins. Sensitization and OVA challenge was shown to accelerate the secretion of Th2 cytokines (IL-4 and IL-5) within the lung, but in the immunized groups, those levels were lower. The administration of Tl-TP and OVA challenge group also evidenced a significant reduction in IL-4 levels as compared to the OVA-challenged group. The concentrations of Th2 cytokines in the Tl-ES and OVA challenge group were more similar to those observed in the OVA-challenged group. The concentration of IL-10 and TGF-beta in the lung was decreased substantially in the OVA-only challenge group, but the Tl-TP immunized group exhibited significantly induced IL-10 cytokine. OVA-specific IgG2a, IgG1, and IgE levels in the immunized groups were significantly lower than those detected in the OVA-challenged group. In conclusion, parasite-derived protein is able to inhibit OVA-specific Th2 responses, and in particular, immunization with parasite proteins exerts a more profound protective effect than is seen with the treatment of allergic reactions. The results of our study are encouraging in terms of our further understanding of the molecular basis of immune evasion by nematodes.